navoximod
oral IDO1 inhibitor Ph. I completed (50-800 mg) for cancer from phenylimidazole + SBDD JPET, April 14, 2023 NewLink Genetics / Genentech
Molecules of the Month - April 2023
oral IDO1 inhibitor Ph. I completed (50-800 mg) for cancer from phenylimidazole + SBDD JPET, April 14, 2023 NewLink Genetics / Genentech
Molecules of the Month - April 2023